The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China

References

• Arthur N, Bentsi-Enchill A, Couper R, et al. The importance of pharmacovigilance - safety monitoring of medicinal products. World HealthOrganization; 2002. [cited 2018 Jul 01]. Available from: http://apps.who.int/medicinedocs/en/d/js4893e/
   Google Scholar
• Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64:743–752.
   PubMed Web of Science ®Google Scholar
• Tandon VR, Mahajan V. Khajuria V, et al. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol. 2015;47:65–71.
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385–396.
   PubMed Web of Science ®Google Scholar
• Biagi C, Montanaro N, Buccellato E. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia–romagna region). Eur J Clin Pharmacol. 2013;69:237–244.
   PubMed Web of Science ®Google Scholar
• Bergvall T, G N N, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37:65–77.
   PubMed Web of Science ®Google Scholar
• Shanmugapriya S, Bhuvaneswari K, Karthika P. Audit to evaluate the completeness of adverse drug reporting in an ADR monitoring centre in Tamilnadu. Indian J Med Specialities. 2017;8:1–4.
   Web of Science ®Google Scholar
• Plessis L, Gómez A, García N, et al. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection. Eur J Clin Pharmacol. 2017;73:751–758.
   PubMed Web of Science ®Google Scholar
• Théophile H, André M, Arimone Y, et al. An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance. J Clin Epidemiol. 2012;65:1069.
   PubMed Web of Science ®Google Scholar
• China Food and Drug Administration (CFDA). National annual report on adverse drug reaction monitoring in 2017. 2018; [cited 2018 Apr 19]. Available from: http://www.cdr-adr.org.cn/xwdt/201804/t20180418_20010.html
   Google Scholar
• Zhang L. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37:765–770.
   PubMed Web of Science ®Google Scholar
• Hou Y, Li X, Wu G, et al. National ADR monitoring system in China. Drug Saf. 2016;39:1043–1051.
   PubMed Web of Science ®Google Scholar
• The standing committee of the national people’s congress of the 525 people’s republic of China ’the pharmaceutical administration law of the people’s republic of China (Presidential Decree 45). 2001 Feb; [cited 2018 Jul 01]. Available from: http://www.sda.gov.cn/WS01/CL0064/23396.html
   Google Scholar
• Ministry of Health and China Food and Drug Administration. The adverse drug reaction reporting and monitoring provision (The Ministry of Health Decree 81). 2011 May; [cited 2018 Jul 01]. Available from: http://www.sda.gov.cn/WS01/CL0053/62621_7.html
   Google Scholar
• Shaanxi Provincial Bureau of Statistics. Shaanxi statistical yearbook. 2017. [cited 2018 Jul 10]. Available from: http://www.shaanxitj.gov.cn/upload/2018/7/zk/indexch.htm
   Google Scholar
• Jiao H. Principles of statistics. Sichuan, China: Southwestern University of Finance and Economics Press; 2004.
   Google Scholar
• Ribeiro A, Lima S, M E Z, et al. Filling quality of the reports of adverse drug reactions received at the pharmacovigilance centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations. Expert Opin Drug Saf. 2017;16:1329–1334.
   PubMed Web of Science ®Google Scholar
• Zhu L, Huang P, Monitoring Status LY. Existing problems of adverse drug reaction in China. Chin Pharm Aff. 2017;30:729–734.
   Google Scholar
• Moore JM, Furberg CD, Mattison CMR. Completeness of serious adverse drug event reports received by the US food and drug administration in 2014. Pharmacoepidemiol Drug Saf. 2016;25:713–718.
   PubMed Web of Science ®Google Scholar
• Mccarthy M. Drug makers’ adverse event reports are often incomplete, US report finds. Bmj. 2015;350(feb04 6):h651.
   PubMedGoogle Scholar
• Ke-Ren T, Jing G, Jian M. Analysis of adverse drug reaction monitoring and inspection system for drug manufacturers in our province. Chin J Pharmacovigilance. 2014;5:285–287.
   Google Scholar
• Huff-Rousselle M, Simooya O, Kabwe V, et al. Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond. Glob Public Health. 2007;2:184–203.
   PubMedGoogle Scholar
• Zhang XM, Niu R, Feng BL, et al. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study. Expert Opin Drug Saf. 2018. DOI:10.1080/14740338.2018.1486820.
   Web of Science ®Google Scholar
• Durrieu G, Jacquot J, Mège M, et al. Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: a descriptive study. Drug Saf. 2016;39:1–7.
   PubMed Web of Science ®Google Scholar
• Banovac M, Candore G, Slattery J, et al. Patient reporting in the EU: analysis of eudravigilance data. Drug Saf. 2017;40:1–17.
   PubMed Web of Science ®Google Scholar
• Kheloufi F, Default A, Rouby F, et al. Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre? Eur J Clin Pharmacol. 2017;6653:1–10.
   Google Scholar
• Rolfes L, H F V, Van D LL, et al. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf. 2017;40:1–8.
   PubMed Web of Science ®Google Scholar
• Lu CF, Cui XK, Liu WW, et al. Exploration on the model of provincial 610 ADR monitoring support the drug supervision. Chin Pharmacovigilance. 2018;15:24–27.
   Google Scholar
• Wu Shifu, Wang Ling, Li Yuji, et al. Research on the public reporting model of adverse drug reactions in China. Chin Med J (Engl). 2017;14:407–412.
   Google Scholar
• Wang X, Lu C, Yujuan Z, et al. Investigation and reflection on the public reporting methods and report contents of adverse drug reactions in China. Chin Pharmacovigilance. 2017;14:413–418.
   Google Scholar
• Combi C, Zorzi M, Pozzani G, et al. From narrative descriptions to MedDRA: automagically encoding adverse drug reactions. Journal of Biomedical Informatics. 2018;84:184–199.
   Google Scholar